Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...